Recent Posts on This Topic | See All >
New data demonstrate anti-tumor activity for ABRAXANE® combination chemotherapy regimen in patients with metastatic pancreatic cancerTags: cancer, clinical trial
[Source: Business Wire] - Abraxis BioScience, Inc., a fully integrated biotechnology company, today announced results from an ongoing phase I/II clinical study evaluating ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) (100, 125 or 150 mg/m2) administered in combination with the standard chemotherapy gemcitabine (1,000 mg/m2), for the treatment of patients with advanced metastatic pancreatic cancer. In a preliminary analysis of 67 patients, investigator-assessed results showed the median survival rate for patients treated with the ABRAXANE/gemcitabine combination was 10.3 months across all dose levels. The combination also resulted in a disease control rate (confirmed complete response (CR), partial response (PR) and stable disease for 16 weeks or longer according to RECIST criteria) of 70 percent. Five percent of patients achieved a CR, 39 percent of patients achieved a PR and 26 percent of patients had stable disease for 16 weeks or longer. Study results also showed a higher response rate among patients who expressed the biomarker, secreted protein acidic and rich in cysteine (SPARC), compared to SPARC negative patients. More specifically, eighty percent of SPARC-positive patients (8 of 10) achieved a response compared to 36 percent (8 of 22) of SPARC-negative patients, (p=0.027). These findings were presented in a poster discussion session of Abstract #4525 on May 31st at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Fla.
For more information click here.
Now available: “Arizona’s Bioscience Roadmap 2014-2025: Advancing the Biosciences and Improving Health Outcomes,” is now available along with its supplement, “Summary of Goals, Strategies, and Potential Actions.” An overview by Walter Plosila, Ph.D., Battelle senior advisor, is also available. The updated Roadmap provides a long-term strategy for Arizona to achieve bioscience success over the next decade.